Health Economics and Outcomes Research (hEOR) is a unit of the Galen Centre for Health and Social Policy and seeks to support and inform healthcare decisions, views and statements with relevant scientific evidence.


Health Economics and Outcomes Research (hEOR), seeks to make significant positive contributions in healthcare by using relevant scientific evidence to inform healthcare decision-making in all strategies, policies and operations for all agencies.

hEOR supports better health care policies by offering insights in economics; and statistical analyses of critical issues. With that hEOR endeavours to use evidence based scientific analysis to help decision makers make informed, and timely decisions.


hEOR’s strategic perspective stresses on projects tackling policy and strategic issues that have effects on the present and will shape the future.

hEOR believes in working diligently, and closely with stakeholders, clients and external experts to: develop significant new policy insights; define strategies, and identify optimal choices.


L22, Common Ground
G016, Jaya One
72A, Jln Professor Diraja Ungku Aziz, Seksyen 13
46200 Petaling Jaya, Selangor, Malaysia

T: +6012 336 2338
E: [email protected]


  • Use relevant scientific evidence to “inform” better health care decision making
  • Drive health economics and outcomes research to connect into a complicated synergy between health systems; and economic theory, its models and techniques; and healthcare decisions made based on evidence
  • Build an active knowledge sharing community and network for health economics and outcomes research


Provides consultancy services for non-profit and for-profit purposes:

  • Scientific research based on evidence. This is based on the core of health economics, economic evaluations, budget impact analysis, value assessments and generations of real-world evidence.
  • Health economics training sessions: Typically all training sessions can be designed for all organizations. Academic excellence in all courses are monitored by a global panel of professors. Training is broken into basic, intermediate and advanced modules.
  • Knowledge sharing opportunities in the form of Health Economic Forums.
  • Personalized case studies and clinical studies upon contract and agreement.


informing healthcare decisions

The hEOR Team

Researchers & Collaborators

Dato Faridah

Dato’ Dr Faridah Aryani Md. Yusof

Distinguished Fellow

Dr. Faridah has extensive experience in drug regulatory affairs working in various positions in the National Pharmaceutical Regulatory Agency (NPRA) for over a period of 18 years, and designated as the Secretary to the Drug Control Authority. She was appointed as the Director of NPRA. She held a few top posts in the Pharmaceutical Services Programme (PSP) and, was promoted as the Senior Director for the PSP in 2020. Being the Senior Director for Pharmaceutical Services, she headed the pharmacy services for the entire country. She retired ending 34.5 years of service in the government, and now serving the Pharmacy School, USM as an Academic Fellow.

Dr. Faridah graduated as a pharmacist and obtained her PhD in Pharmacoeconomics in 2006 from Universiti Sains Malaysia.


Prof. Dr. Nathorn Chaiyakunapruk

Distinguished Fellow

Nathorn (Nui) Chaiyakunapruk is a Professor in the Department of Pharmacotherapy at the University of Utah College of Pharmacy in Salt Lake City. He earned a Doctorate of Pharmacy (PharmD) from the University of Wisconsin-Madison, and his PhD in Pharmaceutical Outcomes Research and Policy Program from the University of Washington.

His expertise is in Health Technology Assessment and Global Health. He has applied several HTA methodologies (Health Economics, Real World Data Analysis, and Evidence Synthesis: systematic review and classical/network meta-analysis/ Umbrella review) to support national and global policy, especially his contributions to the World Health Organization.

His research is in broad areas ranging from infectious diseases, non-communicable diseases, community pharmacy, immunization program, complementary and alternative medicines, pharmacogenomics, and smoking cessation. His current projects have been focused on health equity and global health. He is working on developing an approach to incorporate social determinant of health as part of infectious disease modeling to policy decision making and implementation process.


Dr Ong

Dr Ong Siew Chin


Dr Ong Siew Chin is currently a senior lecturer and programme chairman of the Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia. She completed her PhD degree from the National University of Singapore in the field of pharmacoeconomics and outcomes research. She has served at the National University Hospital Singapore, SingHealth Centre for Health Services Research and Ministry of Health Singapore, Health Technology Assessment, Health Services Research and Evaluation Division prior return to Malaysia.

She is an academic editor for the prestigious PLOS One journal and an editorial board member for the Malaysian Journal of Pharmaceutical Sciences. Her research interests are in pharmacoeconomics and outcomes research, in particular cost-effectiveness, budget impact analysis, cost analysis, cost-of-illness studies, health-related quality-of-life studies, cross-cultural adaptation and validation of questionnaires; pharmacy practice and health services research.

Lana Lai

Dr. Lana Lai


Dr. Lana Lai is a medical statistician at the University of Manchester, UK with an interest in digital learning health systems. She has a background in pharmacy and has experience working with real-world observational studies encompassing a wide range of research methodologies and data sources in the US and UK.

She is also part of Observational Health Data Sciences and Informatics (OHDSI), a global network of scientists working to bring out the value of observational health data through large-scale analytics. To date, she has published more than 30 papers, including characterising patients with COVID-19 and method evaluation in vaccine safety surveillance.